A New Dawn: Ibrilatazar Shatters Survival Records in Deadly Lung Cancer
- Astonishing Breakthrough: AbilityPharma's Ibrilatazar has doubled overall survival for patients battling aggressive squamous non-small cell lung cancer (sq-NSCLC)1, 3.
- Hope Ignited: This innovative drug, with a unique mechanism targeting cellular autophagy, offers a lifeline against a cancer notorious for its grim prognosis and limited treatments3, 7.
- Record Results: Patients receiving Ibrilatazar with chemotherapy saw median overall survival soar to over 22 months, a monumental leap from the 11.3 months seen with historical treatments1.
For too long, a diagnosis of squamous non-small cell lung cancer (sq-NSCLC) has cast a long, grim shadow, offering patients few therapeutic avenues and a bleak outlook3. But now, a beacon of hope emerges. AbilityPharma's groundbreaking drug, Ibrilatazar (ABTL0812), has delivered astonishing results in the ENDOLUNG trial, effectively doubling overall survival in patients1.
When Ibrilatazar was combined with standard chemotherapy, median overall survival skyrocketed to an unprecedented 22.5 months, dwarfing the 11.3 months seen in historical controls1. This isn't just an incremental improvement; it's a potential paradigm shift. As AbilityPharma’s CEO & Co-Founder, ..., stated, "This publication represents a crucial development...a significant milestone in our mission to deliver transformative treatments to cancer patients."
Dr. ..., medical oncologist and first author of the article, highlighted the dire need: "Squamous cell lung cancer is one of the lung cancer subtypes with the fewest therapeutic options and the poorest prognosis. That’s why it is especially relevant that a new molecule like ibrilatazar...has shown promising antitumor activity." Ibrilatazar’s novel approach, inducing cytotoxic autophagy in cancer cells by targeting the PI3K pathway7, is "a very attractive and innovative therapeutic target."
Remarkably, the drug combination also exhibited a good safety profile, not adding significant adverse events beyond standard chemotherapy3. With these "highly promising" results, as described by Dr. ..., fellow senior author, Ibrilatazar, already recognized with an INN by the WHO6, could soon rewrite the treatment playbook for this complex disease, offering precious time and renewed hope to those who desperately need it.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.